H. Lundbeck A/S

🇩🇰Denmark

Country: 🇩🇰Denmark

Ownership: Public, Subsidiary

Established: 2000-01-01

Employees: 5.6K

Market Cap: -

Website: http://www.lundbeck.com

Clinical Trials

A Trial Investigating Lu AF28996 in Adult Japanese Participants With Parkinson's Disease (PD)

Phase 1

Completed

Conditions: Parkinson Disease

Interventions: Drug: Lu AF28996

First Posted Date: 2023-08-22

Last Posted Date: 2023-12-11

Lead Sponsor: H. Lundbeck A/S

Target Recruit Count: 6

Registration Number: NCT06004180

Locations: 🇯🇵
Ehime University Hospital, Ehime, Japan

A Study Investigating Lu AG06474 in Healthy Young Participants

Phase 1

Terminated

Conditions: Healthy Participants

Interventions: Drug: Lu AG06474
Drug: Placebo

First Posted Date: 2023-07-13

Last Posted Date: 2024-11-18

Lead Sponsor: H. Lundbeck A/S

Target Recruit Count: 56

Registration Number: NCT05943327

Locations: 🇺🇸
Quotient Sciences Miami, Miami, Florida, United States

A Study of Eptinezumab in Pediatric Participants With Episodic Migraine

Phase 3

Recruiting

Conditions: Episodic Migraine

Interventions: Drug: Placebo
Drug: Eptinezumab

First Posted Date: 2023-06-09

Last Posted Date: 2024-12-11

Lead Sponsor: H. Lundbeck A/S

Target Recruit Count: 315

Registration Number: NCT05897320

Locations: 🇮🇹
Fondazione IRCCS Istituto Neurologico Carlo Besta, Milano, Lombardia, Italy
🇵🇹
ULS de São João, EPE - Hospital de São João, Porto Covo, Portugal
🇹🇷
Mersin Universitesi Tip Fakultesi Hastanesi, Mersin, Turkey

and more 47 locations

Study of Lu AG13909 in Participants With Congenital Adrenal Hyperplasia

Phase 1

Recruiting

Conditions: Congenital Adrenal Hyperplasia

Interventions: Drug: Lu AG13909

First Posted Date: 2023-01-03

Last Posted Date: 2024-07-05

Lead Sponsor: H. Lundbeck A/S

Target Recruit Count: 12

Registration Number: NCT05669950

Locations: 🇬🇧
University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom
🇸🇪
Karolinska University Hospital/ Huddinge, Huddinge, Sweden
🇸🇪
Sahlgrenska University Hospital, Gothenburg, Sweden

and more 2 locations

Observational Study in Multiple System Atrophy

Completed

Conditions: Multiple System Atrophy

Interventions: Diagnostic Test: plasma NfL and brain MRI (vMRI, DTI, and ASL [if feasible]) only for the EU cohort

First Posted Date: 2022-07-12

Last Posted Date: 2024-04-09

Lead Sponsor: H. Lundbeck A/S

Target Recruit Count: 90

Registration Number: NCT05453058

Locations: 🇨🇳
The Second Affiliated Hospital of Soochow University, Suzhou, China
🇨🇳
Beijing Tiantan Hospital, Capital Medical University, Beijing, China
🇨🇳
Beijing Xuanwu Hospital, Capital Medical University, Beijing, China

and more 5 locations

A Study of Eptinezumab in Participants With Migraine and Medication Overuse Headache

Phase 4

Active, not recruiting

Conditions: Medication Overuse Headache
Migraine

Interventions: Drug: Eptinezumab
Drug: Placebo

First Posted Date: 2022-07-11

Last Posted Date: 2024-12-20

Lead Sponsor: H. Lundbeck A/S

Target Recruit Count: 570

Registration Number: NCT05452239

Locations: 🇸🇪
Skaneuro Privatmottagning, Lund, Skane Lan, Sweden
🇫🇷
Hospices Civils de Lyon - Hôpital Pierre Wertheimer, Bron, Rhône, France
🇫🇷
AP-HP - Hopital Lariboisiere, Paris, France

and more 73 locations

A Brain Imaging PET Study of [11C]-Lu AF88370 in Healthy Adult Male Participants

Phase 1

Completed

Conditions: Healthy Participants

Interventions: Drug: [11C]-Lu AF88370

First Posted Date: 2022-04-11

Last Posted Date: 2022-07-14

Lead Sponsor: H. Lundbeck A/S

Target Recruit Count: 6

Registration Number: NCT05320302

Locations: 🇬🇧
Invicro, London, United Kingdom

A Brain Imaging PET Study of [11C]-Lu AF90103 in Healthy Adult Male Participants

Phase 1

Completed

Conditions: Healthy Young Men

Interventions: Drug: [11C]-Lu AF90103

First Posted Date: 2022-04-01

Last Posted Date: 2022-07-14

Lead Sponsor: H. Lundbeck A/S

Target Recruit Count: 8

Registration Number: NCT05306366

Locations: 🇸🇪
Karolinska Trial Alliance, Huddinge, Sweden

A Study Investigating the Movement of Lu AG09222 Into, Through, and Out of the Body of Healthy Caucasian, Chinese, and Japanese Participants

Phase 1

Completed

Conditions: Migraine

Interventions: Drug: Lu AG09222
Drug: Placebo

First Posted Date: 2022-03-31

Last Posted Date: 2022-11-10

Lead Sponsor: H. Lundbeck A/S

Target Recruit Count: 52

Registration Number: NCT05304910

Locations: 🇺🇸
PAREXEL International, Glendale, California, United States

Real World Effectiveness of Eptinezumab in Participants With Migraine

Phase 4

Terminated

Conditions: Migraine

Interventions: Drug: Onabotulinumtoxin-A
Drug: Eptinezumab
Drug: Erenumab
Drug: Fremanezumab
Drug: Galcanezumab

First Posted Date: 2022-03-17

Last Posted Date: 2024-05-29

Lead Sponsor: H. Lundbeck A/S

Target Recruit Count: 32

Registration Number: NCT05284019

Locations: 🇺🇸
Gilbert Neurology Partners/ CCT Research, Gilbert, Arizona, United States
🇺🇸
Ki Clinical Research LLC, dba New England Institute for Clinical Research, Stamford, Connecticut, United States
🇺🇸
Innovation Medical Group, Palmetto Bay, Florida, United States

and more 7 locations

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy